Literature DB >> 17181487

Percutaneous radiofrequency ablation: minimally invasive therapy for renal tumors.

Kamran Ahrar1, Michael J Wallace, Surena F Matin.   

Abstract

Currently, up to 60% of renal tumors are detected incidentally by abdominal imaging. Most of these tumors are small and localized to the kidney. Owing to the shift to lower stage at diagnosis, radical nephrectomy has fallen out of favor and has been replaced by nephron-sparing surgery. Currently, partial nephrectomy is the treatment of choice for patients with small renal tumors. As the trend towards less invasive therapy continues, laparoscopic and percutaneous ablation techniques have gained popularity for the treatment of renal tumors in patients who are high-risk surgical candidates, or have a solitary kidney, limited renal function or multifocal disease. Percutaneous radiofrequency ablation is a safe, minimally invasive treatment option for those patients.

Entities:  

Mesh:

Year:  2006        PMID: 17181487     DOI: 10.1586/14737140.6.12.1735

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  3 in total

1.  Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer.

Authors:  Mostafa Atri; Mark R Gertner; Masoom A Haider; Robert A Weersink; John Trachtenberg
Journal:  Can Urol Assoc J       Date:  2009-04       Impact factor: 1.862

2.  Real-time magnetic resonance imaging-guided cryoablation of small renal tumors at 1.5 T.

Authors:  Kamran Ahrar; Judy U Ahrar; Sanaz Javadi; Li Pan; Denái R Milton; Christopher G Wood; Surena F Matin; R Jason Stafford
Journal:  Invest Radiol       Date:  2013-06       Impact factor: 6.016

Review 3.  Design and Challenges of Sonodynamic Therapy System for Cancer Theranostics: From Equipment to Sensitizers.

Authors:  Zhuoran Gong; Zhifei Dai
Journal:  Adv Sci (Weinh)       Date:  2021-03-12       Impact factor: 16.806

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.